Oyavas 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/09/2023 
19/10/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
II/0022 
B.I.e.2 - Introduction of a post approval change 
14/09/2023 
n/a 
management protocol related to the AS 
IB/0024/G 
This was an application for a group of variations. 
11/07/2023 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0023 
B.I.e.5.c - Implementation of changes foreseen in an 
04/07/2023 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0021 
B.I.a.4.z - Change to in-process tests or limits 
08/05/2023 
n/a 
applied during the manufacture of the AS - Other 
variation 
IB/0020 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
28/04/2023 
19/10/2023 
SmPC 
SmPC was updated to reflect extension of shelf life. 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
II/0019 
B.I.e.2 - Introduction of a post approval change 
09/02/2023 
n/a 
management protocol related to the AS 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
13/10/2022 
09/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02202 
bevacizumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/403/202202. 
IB/0018/G 
This was an application for a group of variations. 
20/10/2022 
n/a 
B.I.e.5.c - Implementation of changes foreseen in an 
approved change management protocol - For a 
biological/immunological medicinal product 
B.II.g.5.c - Implementation of changes foreseen in 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
an approved change management protocol - For a 
biological/immunological medicinal product 
IB/0017/G 
This was an application for a group of variations. 
11/10/2022 
n/a 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
IB/0015 
B.II.b.1.z - Replacement or addition of a 
26/08/2022 
n/a 
manufacturing site for the FP - Other variation 
IB/0016/G 
This was an application for a group of variations. 
25/08/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
IB/0013 
B.II.g.4.b - Changes to an approved change 
03/08/2022 
n/a 
management protocol - Minor changes that do not 
change the strategy defined in the protocol 
IA/0014/G 
This was an application for a group of variations. 
21/07/2022 
n/a 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IA/0012 
A.7 - Administrative change - Deletion of 
04/07/2022 
n/a 
manufacturing sites 
IB/0011/G 
This was an application for a group of variations. 
04/07/2022 
09/12/2022 
SmPC and PL 
To update sections 4.2 and 6.6 of the SmPC to reinstate 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the statement “do not shake”. 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II/0009/G 
This was an application for a group of variations. 
02/06/2022 
n/a 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
N/0008 
Minor change in labelling or package leaflet not 
17/03/2022 
09/12/2022 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0007 
B.I.b.2.a - Change in test procedure for AS or 
07/02/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/01/2022 
09/12/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0004 
B.I.b.2.d - Change in test procedure for AS or 
13/01/2022 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IAIN/0005 
B.II.b.1.a - Replacement or addition of a 
17/11/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
II/0003/G 
This was an application for a group of variations. 
16/09/2021 
n/a 
B.II.b.4.c - Change in the batch size (including batch 
size ranges) of the finished product - The change 
requires assessment of the comparability of a 
biological/immunological medicinal product or a new 
bioequivalence study 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IB/0002 
B.I.e.5.c - Implementation of changes foreseen in an 
22/07/2021 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
03/05/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
